The FDA approve esketamine nasal spray for severe depression
Saima Sharmeen
The FDA approve esketamine nasal spray for severe depression


The Food and Drug Administration (FDA) have just granted approval of the drug esketamine (Spravato) to the Johnson & Johnson company Janssen Pharmaceuticals Inc.

The fast-acting nasal spray is for use in conjunction with an oral antidepressant in adults with treatment-resistant depression, note the federal agency.

According to its developer, the drug uses the "first new mechanism of action in decades to treat" major depressive disorder.

The aim is that healthcare providers will prescribe the nasal spray to people with major depressive disorder who have tried and received no benefit from at least two antidepressant treatments.

The FDA also say that the drug will only be available through a system of tight distribution and monitoring.


Read more: https://www.medicalnewstoday.com/articles/324656.php
S●●●●●●a J●a and 7 others like this
Like
Comment
Share